Literature DB >> 18424377

Is facial involvement a sign of severe psoriasis?

Filiz Canpolat1, Bengü Cevirgen Cemil, Fatma Eskioğlu, Havva Kaya Akis.   

Abstract

Facial involvement in psoriasis receives little attention in standard descriptions of the disease. To our knowledge there has been only one comparison study on the severe of psoriasis between patients with and without facial involvement. The purpose of this study was to define the prevalence and characteristics of facial involvement, and to compare the severity of psoriasis between patients with and without facial involvement. A total of 120 consecutive patients with psoriasis seen in our polyclinic between January 2005 and May 2005 were enrolled in this study. They were categorized into patients with and without facial psoriasis. The age of onset, family history, nail and joint involvement, associated skin or systemic disease, history of phototherapy or systemic therapy, extent of involvement, the effect of external factors and Psoriasis Area and Severity Index (PASI) scores were recorded. Patients who had PASI score lower than 5 were excluded from the study. Patients with facial psoriasis frequently report early onset, or long duration, and tend to have more extensive disease and more intensive treatment. The patients with facial psoriasis have more positive family histories and Koebner responses. The nail, joint involvement and pruritus did not appear to influence the presence of facial psoriasis. Facial involvement in psoriasis is much more common than generally appreciated. This study demonstrates the significance of facial involvement in psoriasis. In view of its significance as a marker of severe disease, extra care must be taken during treatment to ensure clearance from this site.

Entities:  

Mesh:

Year:  2008        PMID: 18424377     DOI: 10.1684/ejd.2008.0363

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN: 1167-1122            Impact factor:   3.328


  3 in total

Review 1.  Underdiagnosed and undertreated psoriasis: Nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails.

Authors:  Joseph F Merola; Abrar Qureshi; M Elaine Husni
Journal:  Dermatol Ther       Date:  2018-03-06       Impact factor: 2.851

2.  Efficacy of Secukinumab for Moderate-to-Severe Head and Neck Psoriasis Over 52 Weeks: Pooled Analysis of Four Phase 3 Studies.

Authors:  Leon Kircik; Joseph Fowler; Jonathan Weiss; Xiangyi Meng; Adriana Guana; Judit Nyirady
Journal:  Dermatol Ther (Heidelb)       Date:  2016-08-30

Review 3.  Treating pediatric plaque psoriasis: challenges and solutions.

Authors:  Jayakar Thomas; Kumar Parimalam
Journal:  Pediatric Health Med Ther       Date:  2016-04-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.